To Guide Cancer Therapy, Device Quickly Tests Drugs on Tumor Tissue
December 12, 2018 | MITEstimated reading time: 6 minutes
MIT researchers have 3-D printed a novel microfluidic device that simulates cancer treatments on biopsied tumor tissue, so clinicians can better examine how individual patients will respond to different therapeutics—before administering a single dose.
Testing cancer treatments today relies mostly on trial and error; patients may undergo multiple time-consuming and hard-to-tolerate therapies in pursuit of one that works. Recent innovations in pharmaceutical development involve growing artificial tumors to test drugs on specific cancer types. But these models take weeks to grow and don’t account for an individual patient’s biological makeup, which can affect treatment efficacy.
The researchers’ device, which can be printed in about one hour, is a chip slightly larger than a quarter, with three cylindrical “chimneys” rising from the surface. These are ports used to input and drain fluids, as well as remove unwanted air bubbles. Biopsied tumor fragments are placed in a chamber connected to a network of channels that deliver fluids—containing, for instance, immunotherapy agents or immune cells—to the tissue. Clinicians can then use various imaging techniques to see how the tissue responds to the drugs.
A key feature was using a new biocompatible resin—traditionally used for dental applications—that can support long-term survival of biopsied tissue. Although previous 3-D-printed microfluidics have held promise for drug testing, chemicals in their resin usually kill cells quickly. The researchers captured fluorescence microscopy images that show their device, called a tumor analysis platform (TAP), kept more than 90% of the tumor tissue alive for at least 72 hours, and potentially much longer.
Because the 3-D printed device is easy and cheap to fabricate, it could be rapidly implemented into clinical settings, the researchers say. Doctors could, for instance, print out a multiplexed device that could support multiple tumor samples in parallel, to enable modeling of the interactions between tumor fragments and many different drugs, simultaneously, for a single patient.
“People anywhere in the world could print our design. You can envision a future where your doctor will have a 3-D printer and can print out the devices as needed,” says Luis Fernando Velásquez-García, a researcher in the Microsystems Technology Laboratories and co-author on a paper describing the device, which appears in the December issue of the Journal of Microelectromechanical Systems. “If someone has cancer, you can take a bit of tissue in our device, and keep the tumor alive, to run multiple tests in parallel and figure out what would work best with the patient’s biological makeup. And then implement that treatment in the patient.”
A promising application is testing immunotherapy, a new treatment method using certain drugs to rev up a patient’s immune system to help it fight cancer. (This year’s Nobel Prize in physiology or medicine was awarded to two immunotherapy researchers who designed drugs that block certain proteins from preventing the immune system from attacking cancer cells.) The researchers’ device could help doctors better identify treatments to which an individual is likely to respond.
“Immunotherapy treatments have been specifically developed to target molecular markers found on the surface of cancer cells. This helps to ensure that the treatment elicits an attack on the cancer directly while limiting negative impacts on healthy tissue. However, every individual’s cancer expresses a unique array of surface molecules—as such, it can be difficult to predict who will respond to which treatment. Our device uses the actual tissue of the person, so is a perfect fit for immunotherapy,” says first author Ashley Beckwith SM ’18, a graduate researcher in Velásquez-García’s research group.
Co-author on the paper is Jeffrey T. Borenstein, a researcher at Draper.
Page 1 of 2
Suggested Items
Inkjet Solder Mask ‘Has Arrived’
04/10/2024 | Pete Starkey, I-Connect007I was delighted to be invited to attend an interactive webinar entitled “Solder Mask Coating Made Easy with Additive Manufacturing,” hosted by SUSS MicroTec Netherlands in Eindhoven. The webinar was introduced and moderated by André Bodegom, managing director at Adeon Technologies, and the speakers were Mariana Van Dam, senior product manager PCB imaging solutions at AGFA in Belgium; Ashley Steers, sales manager at Electra Polymers in the UK; and Dr. Luca Gautero, product manager at SUSS MicroTec Netherlands.
NetVia Group Acquires Direct Imaging from Mivatek
04/09/2024 | Miva TechnologiesMiva Technologies is pleased to announce NetVia Group, Irving, TX has acquired a new Miva 2400NG Dual Tray Direct Imaging System with 30-micron capabilities for inner, outer and soldermask imaging.
Teledyne to Acquire Adimec
02/13/2024 | TeledyneTeledyne Technologies Incorporated announced that it has entered into an agreement to acquire Adimec Holding B.V. and its subsidiaries.
Real Time with... productronica 2023: MivaTek Global Advances Technology With High-res Imaging System
12/08/2023 | Real Time with...productronicaMivaTek's Brendan Hogan talks about how the company employs Digitally Adaptive Rasterization Technology (DART) in their high-res imaging equipment. He also shares how the blurred line between semiconductors and microelectronics is driving broader application of the imaging process.
Keysight Enables Validation of Arbe 4D Imaging Radar Chipset
11/30/2023 | Keysight Technologies, Inc.Keysight Technologies, Inc. announces that Arbe has selected the E8719A Radar Target Solution (RTS) to test the Arbe 4D imaging radar chipset for automotive applications.